Ajanta Pharma (Large Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Ajanta Pharma Limited |
|||
|
Price: ₹2,866.45 | ||
| 52 Week Low: ₹1,850.25 52 Week High: ₹3,485.00 |
|||
| Market Capital: 35,728.1 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Ajanta Pharma Share Price Target For 2024
- 1.1.1: Ajanta Pharma Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Ajanta Pharma Share Price Target For 2025
- 1.2.1: Ajanta Pharma Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Ajanta Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Ajanta Pharma Brief Company Overview
- 4: Ajanta Pharma Financial Performance
- 4.0.1: Is Ajanta Pharma A Good Buy For Long Term?
To predict the Ajanta Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Ajanta Pharma Share Price Target For 2024
The line chart displays the monthly closing prices of Ajanta Pharma with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Ajanta Pharma shares in 2024, see the table below.
Ajanta Pharma Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 2936.55 (+2.44%) | Price Action: 22 Nov 2024 Low |
| 2024 Target 2 | 2905.0 (+1.34%) | Price Action: 05 Dec 2024 Low |
| 2024 Target 1 | 2875.1 (+0.30%) | Price Action: 14 Nov 2024 High |
| Current Price | 2866.45 | Ajanta Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 2794.7 (-2.51%) | Price Action: 16 Dec 2024 Low |
| Stop Loss 2 | 2755.55 (-3.87%) | Price Action: Nov 2024 Low |
| Stop Loss 3 | 2693.09 (-6.05%) | Price Action: Jul 2024 High |
Short-Term Technical Outlook
Current Technical Position: Ajanta Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹2911.5 serves as the nearest technical reference point.
Historical Returns: 3-month: -9.66% | 6-month: +26.46% | 1-year: +40.44%
Ajanta Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Ajanta Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Ajanta Pharma shares in 2025, see the table below.
Ajanta Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 3960.86 (+38.17%) | Price Action: Chart |
| 2025 Target 2 | 3887.01 (+35.60%) | Fibonacci Extension Level 64.90% |
| 2025 Target 1 | 3840.95 (+33.99%) | Fibonacci Extension Level 123.60% |
| Current Price | 2866.45 | Ajanta Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 2563.03 (-10.59%) | Technical Indicator: MA250 |
| Stop Loss 2 | 2517.14 (-12.19%) | Price Action: May 2024 High |
| Stop Loss 3 | 2472.54 (-13.75%) | Price Action: Jun 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Ajanta Pharma is currently trading at 62.2% of its 52-week range (₹1850.25 - ₹3485).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +40.44% | 3-year: +98.60% | 5-year: +360.38%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Ajanta Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,866.45 | ||
| 2024 | ₹3,708.41 | +29.37% | ₹3,764.04 |
| 2025 | ₹4,754.23 | +28.20% | ₹4,825.54 |
| 2026 | ₹5,934.44 | +24.82% | ₹6,023.46 |
| 2027 | ₹7,515.42 | +26.64% | ₹7,699.90 |
| 2028 | ₹9,482.69 | +26.18% | ₹9,624.93 |
| 2029 | ₹10,958.95 | +15.57% | ₹11,123.33 |
| 2030 | ₹11,436.54 | +4.36% | ₹11,608.09 |
| 2031 | ₹12,445.31 | +8.82% | ₹13,316.10 |
| 2032 | ₹14,277.14 | +14.72% | ₹15,188.30 |
| 2033 | ₹16,713.30 | +17.06% | ₹17,060.51 |
| 2034 | ₹18,209.50 | +8.95% | ₹18,482.64 |
| 2035 | ₹18,118.85 | -0.50% | ₹18,932.71 |
| 2036 | ₹18,956.18 | +4.62% | ₹20,804.91 |
| 2037 | ₹21,038.86 | +10.99% | ₹22,677.11 |
| 2038 | ₹23,943.90 | +13.81% | ₹24,549.32 |
| 2039 | ₹24,667.32 | +3.02% | ₹25,037.33 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Ajanta Pharma Brief Company Overview
Ajanta Pharma Limited Founded in 1973, Ajanta Pharma is a renowned specialty pharmaceutical company headquartered in Mumbai, India. They specialize in developing, manufacturing, and marketing various therapeutic segments, including antimalarial, cardiology, ophthalmology,...
dermatology, and pain management. Diverse Product Range Tablets Capsules Powder Liquid Jelly Ointments Sterile eye drops Active pharma ingredient Global Presence Ajanta Pharma has a strong presence in India, Africa, the rest of Asia, the United States, and internationally, showcasing its global reach. Commitment to Excellence The company is committed to providing high-quality products and services, maintaining its reputation in the industry for excellence.Ajanta Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 35,728.1 Crore | Market valuation of Ajanta Pharma's shares. |
| Revenue (TTM) | 4,490.79 Crore | Total revenue generated by Ajanta Pharma over the past twelve months. |
| Net Income (TTM) | +8,750,000,128.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +25.48% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +19.48% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+15.40% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+10.80% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.89 | Company's total debt divided by total shareholder equity. |
| Total Debt | 32.79 Crore | Sum of Ajanta Pharma's current & long-term financial obligations. |
| Total Cash | 741.91 Crore | Total amount of liquid funds available to Ajanta Pharma. |
| Beta | 0.1 | Beta is less than 1 indicating that the Ajanta Pharma's price is less volatile than the market. |
Is Ajanta Pharma A Good Buy For Long Term?
Ajanta Pharma (market cap: ₹35,728.1 crore) shows strong financial health with ₹875 crore net profit (19.48% margin) on ₹4,490.79 crore revenue (TTM). The company boasts impressive growth: 10.8% YoY earnings growth in Q2 2024-25, and substantial returns over various periods (17.08% past 3 months, 68.04% past 12 months, 274.84% past 5 years). Low debt (₹32.79 crore) and healthy cash (₹741.91 crore) further strengthen its position. Considering this robust performance and growth trajectory, Ajanta Pharma is a good buy for the long term.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
